TG Therapeutics, Inc. (TGTX)

TG Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	616.29	329	233.66	2.79	6.69
Revenue Growth (YoY)	87.32%	40.80%	8290.02%	-58.36%	4300.66%
Cost of Revenue	100.71	38.49	14.13	0.27	0.79
Gross Profit	515.57	290.52	219.53	2.52	5.9
Selling, General & Admin	232.03	154.3	122.71	95.48	128.09
Research & Development	160.22	94.29	76.19	125.35	222.58
Total Operating Expenses	392.25	248.59	198.9	220.84	350.67
Operating Income	123.32	41.93	20.63	-218.32	-344.77
Interest Expense	-26.73	-24.03	-12.62	-10.19	-5.64
Other Non-Operating Income (Expense)	10.79	7.69	5.04	4.7	2.31
Total Non-Operating Income (Expense)	-15.93	-16.34	-7.57	-5.5	-3.33
Pretax Income	107.39	25.59	13.06	-223.81	-348.1
Provision for Income Taxes	339.79	-2.21	-0.39	-	-
Net Income	447.18	23.38	12.67	-223.81	-348.1
Net Income to Common	447.18	23.38	12.67	-223.81	-348.1
Net Income Growth	1812.41%	84.52%	-	-	-
Shares Outstanding (Basic)	144	145	142	135	132
Shares Outstanding (Diluted)	161	160	149	135	132
Shares Change (YoY)	0.67%	7.96%	9.67%	2.41%	14.64%
EPS (Basic)	3.10	0.16	0.09	-1.65	-2.63
EPS (Diluted)	2.77	0.15	0.09	-1.65	-2.63
EPS Growth	1746.67%	66.67%	-	-	-
Free Cash Flow	-24.99	-40.56	-31.41	-176.18	-296.04
Free Cash Flow Per Share	-0.15	-0.25	-0.21	-1.30	-2.24
Gross Margin	83.66%	88.30%	93.95%	90.48%	88.19%
Operating Margin	20.01%	12.74%	8.83%	-7838.99%	-5154.28%
Profit Margin	72.56%	7.11%	5.42%	-8036.34%	-5204.08%
FCF Margin	-4.05%	-12.33%	-13.44%	-6326.18%	-4425.70%
EBITDA	123.38	42	20.84	-218.01	-344.49
EBITDA Margin	20.02%	12.76%	8.92%	-7828.11%	-5150.07%
EBIT	123.32	41.93	20.63	-218.32	-344.77
EBIT Margin	20.01%	12.74%	8.83%	-7838.99%	-5154.28%
Effective Tax Rate	316.41%	-8.64%	-2.99%	0.00%	0.00%

Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q